Biochemical and Hematological Impact of Hepatitis C Virus (HCV) on Human Immunodeficiency Virus (HIV) Infected Persons on Antiretroviral Drugs (ARDs) in Nigeria

Main Article Content

Ya’aba Yakubu
Mohammed Shehu Busu
Nfongeh Joseph Fuh
Olatunji Kazeem Toyosi
Abubakar Aisha
Usoroh Mary
Daniel Oluwaseun Christiana
Abdulmumin Adam Raji


Introduction: Biochemical and hematological abnormalities are among most common clinico-pathological manifestations of HIV/AIDS infected persons on antiretroviral drugs (ARDs). Hepatitis C Virus (HCV) infection are known to influence progression and management of HIV infection. Data are limited regarding the impact of ARDs on HIV/HCV co-infected persons in Nigeria. Hence, this study evaluated the biochemical and hematological impact of HCV on prognosis of HIV persons taking ARDs.

Materials and Methods: 2,322 HIV infected persons were screened for HCV. One hundred and nine were co-infected with HCV; and were cross-sectional monitored on ARDs for fifteen months at hospitals in North Central Nigeria for changes in clinical profiles. The determination of Alanine aminotransferase (ALT), Aspartate transaminase (AST), Packed cell volume (PCV) and White blood cells count (WBC) estimations were reviewed every 3 months for each of the person using Reflotron plus machine and hematological analyzer according to the manufacturer’s instructions.

Results: The results showed an increase in both HIV mono-infected and co-infected patients, with raised in AST from 18.46±0.73 to 34.32±0.6053U/l, ALT from 19.37±0.6804 to 34.87±0.5637U/l, PCV from 34.20±0.2998 to 34.89±0.4895% and WBC from 3.50x109±0.0816 to 6.67x109±0.1204 cells/L and AST from 17.35±0.1542 to 34.49±0.0981U/l, ALT from 17.67±0.1412 to 34.80±0915U/l, PCV from 36.74±0.2902 to 38.37±0.4399% and WBC from 3.90x109±0.0251 to 6.19x109±0.0178 cells/L.

Conclusion: It was found that PCV and WBC count values were positively affected despite HCV replication and AST and ALT enzyme levels for both HIV-mono and co-infected persons were slightly elevated. Therefore, efforts addressing viral hepatitis co-infections at the early stage of ARDs initiation under qualified clinician should be of paramount important.

Antiretroviral drugs, aspartate transaminase, alanine aminotransferase, white blood cells count, packed cell volume, clinico-pathological.

Article Details

How to Cite
Yakubu, Y., Busu, M., Fuh, N., Toyosi, O., Aisha, A., Mary, U., Christiana, D., & Raji, A. (2019). Biochemical and Hematological Impact of Hepatitis C Virus (HCV) on Human Immunodeficiency Virus (HIV) Infected Persons on Antiretroviral Drugs (ARDs) in Nigeria. International Blood Research & Reviews, 10(1), 1-10.
Original Research Article


UNAIDS. The joint United Nations Programme on HIV and AIDS. Nigeria Country Progress Report; 2017.
Published 2016.
(Accessed July 22, 2017)

Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Schulze Zur Wiesch Jl. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1. Blood. 2005;105(3):1170–8.

Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology. 2008;135(1):226–33.

Allison RD, Katsounas A, Koziol DE, Kleiner DE, Alter HJ, Lempicki RA. Association of interleukin-15-induced peripheral immune activation with hepatic stellate cell activation in persons coinfected with hepatitis C virus and HIV. Journal of Infectious Diseases. 2009; 200(4):619–23.

Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C co-infected patients. Hepatology. 1999;30:1054-1058.

Feld JJ, Ocama P, Ronald A. The liver in HIV in Africa. Antivir Ther. 2005;10:953-965.

Rockstroh JK. Influence of viral hepatitis on HIV infection. J Hepatology. 2006;44: S25-27.

Gravitz L. Introduction: A smouldering public-health crisis. Nature. 2011; 474(7350):S2– 4.

Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV-HCV coinfection—a global challenge. New England Journal of Medicine. 2012;366(19):1749–52.

Bonacini M, Louie S, Bzowej N, Wohl AR. Survival in patients with HIV infection and viral hepatitis B or C: A cohort study. AIDS. 2004;18(15):2039–45.

Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013;57(1): 249–57.

Thomas DL. Growing importance of liver diseases in HIV-infected persons. Hepatology. 2006;43(2):S221-S229.

N´ u˜nez M, Lana R, Mendoza JL, Mart´ın-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes. 2001;27(5):426–431.

Richardson J, Melester D. Treatment AIDS. Clinical Liver Disease. 2008;7:475–499.

Crum-Cianflone N, Collins G, Medina S. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clinical Gastroenterology and Hepatology. 2010;8(2):183–191.

Butt A. Epidemiology of Liver Disease in Human Immunodeficiency Virus Infected Persons; 2012.

Available: download document/9781441917119-c1.pdf? SGWID=0-0-45-1260039-p174243173.

Salond E. Haematologic complications of HIV infection. AIDS Reviews. 2005;7:187-196.

Cosby CD. Hematologic disorders associated with human immunodeficiency virus and AIDS. Journal of Infusion Nurse. 2007;30(1):22-32.

Okeke TC, Obi SN, Okezie OA, Ugwu EO, Akogu SP. Co-infection with hepatitis B and C viruses among HIV positive pregnant women in Enugu south east, Nigeria. Nigeria Journal of Medicine. 2012; 21:57-60.

Ya’aba Y, Mohammed SB, Ibrahim K, Uba A, Oladosu P. Epidemiology of hepatitis C Virus (HCV) in healthy adults and human immmunodeficency virus (HIV) infected patients in North Central Zone, Nigeria. European Journal of Pharmaceutical and Medical Research. 2016;3(8):06-11.

Population Census. Report of National Population Commission Nigeria on the 2006 census.

Chung R. Management of HIV/HCV co-infection. The PRN Notebook. 2004;9(1): 14-19.

Gatti F, Nasta, A et al. Treating Hepatitis C Virus in HIV patients: Are side effects a real obstacle? AIDS Rev. 2007;9:16-24.

Pryce C, Pierre RB, Steel-Duncan J, Evans-Gilbert T, Palmer P, Moore J. Safety of antiretroviral drug therapy in Jamaican children with HIV/AIDS. West Indian Medical Journal. 2008;57(3):238-45.

Kredo T, Van der Walt JS, Siegfried N, Cohen K. Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst Rev. 2009;(3): CD007268.

Watkins BA, Dom HH, Kelly WB. Specific tropifm of HIV-1 for microghaceus in primary human brain culture. Science. 1990;249(4968):549-554.

Sherman KE, Freeman S, Harrison S, Andron L. Prevalence of antibody to hepatitis c virus in patients infected with the human immunodeficiency virus. Journal of Infectious Diseases. 1991;163: 414-5.

Gretch DR. Diagnostic tests for hepatitis C. Hepatology. 1997;26(Suppl)43s.

Oshikoya KA, Lawal S, Oreagba IA, Awodele O, Olayemi SO, Iroha EO, Ezeaka VC, Temiye EO, Akinsulie AO, Opanuga O, Adeyemo T, Lesi F, Akanmu AS. Adverse Events in HIV-infected Children on Antiretroviral Therapy at a Teaching Hospital in Lagos, Nigeria: A Retrospective Study. Advance Pharmacoepea Drug Saf. 2012;1:117.

Derbe M, Monga DP, Daka D. Immunological response among Gravitz L (2011). HIV/AIDS patients before and after ART therapy at Zewuditu Hospital Addis Ababa, Ethiopia. Am J Res Comm. 2013; 1(1):103-115.

Chukwurah FE, Echeobi D, Nneli, RD. Hematological profile of immunodeficient (HIV) seropositive patients on antiretroviral (ARV) therapy implication of nutrition. Reseach Journal of Medical Science. 2007;1:242-244.